Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology

MT Newswires Live2025-12-23

Ginkgo Bioworks (DNA) is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.

The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.

The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.

Ginkgo plans to support the program with its cell and enzyme engineering capabilities.

Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.

Ginkgo shares rose 8% in recent Monday trading.

Price: 8.75, Change: +0.65, Percent Change: +7.96

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593437717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 03:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593437717","market":"sh","top_or_hot":-1,"title":"Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks</a> (DNA) is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.</p><p>The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.</p><p>The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.</p><p>Ginkgo plans to support the program with its cell and enzyme engineering capabilities.</p><p>Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.</p><p>Ginkgo shares rose 8% in recent Monday trading.</p><p>Price: 8.75, Change: +0.65, Percent Change: +7.96</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-23 03:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks</a> (DNA) is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.</p><p>The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.</p><p>The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.</p><p>Ginkgo plans to support the program with its cell and enzyme engineering capabilities.</p><p>Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.</p><p>Ginkgo shares rose 8% in recent Monday trading.</p><p>Price: 8.75, Change: +0.65, Percent Change: +7.96</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4109","symbol_name":"特种化学制品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593437717","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593437717","pubTimestamp":1766433229,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ginkgo Bioworks  is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.Ginkgo plans to support the program with its cell and enzyme engineering capabilities.Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.Ginkgo shares rose 8%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4109":"特种化学制品","HBCP":"Home Bancorp Inc","BK4211":"区域性银行","DNA.AU":"DONACO INTL LTD","DNA":"Ginkgo Bioworks Holdings Inc.","BK4139":"生物科技","BK7078":"赌场与赌博","BK4195":"互助储蓄与抵押信贷金融服务","BK4121":"生命科学工具和服务"},"translate_title":"Ginkgo Bioworks与卡内基梅隆大学合作开发家庭癌症检测技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA.AU":1,"DNA":1,"HBCP":1.5},"content_text":"Ginkgo Bioworks (DNA) is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.Ginkgo plans to support the program with its cell and enzyme engineering capabilities.Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.Ginkgo shares rose 8% in recent Monday trading.Price: 8.75, Change: +0.65, Percent Change: +7.96","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593437717","isCrawlerRequest":true}